Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Net Cash Flow for 18 consecutive years, with $202.0 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 112.26% year-over-year to $202.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 264.3% YoY) and the FY2025 annual result came in at $235.0 million, down 5.24% from the prior year.
• Net Cash Flow declined to $202.0 million in Q1 2026 per TEVA's latest filing, from $1.4 billion in the prior quarter.
• Over the last five years, Net Cash Flow for TEVA reached as high as $1.4 billion in Q4 2025 and fell as low as -$1.6 billion in Q1 2025.
• A 5-year average of $109.8 million and a median of $114.0 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow soared 1686.11% — and 2025, when it tumbled 1158.02%.
• Year by year, Net Cash Flow stood at $430.0 million in 2022, then soared by 111.4% to $909.0 million in 2023, then plunged by 88.67% to $103.0 million in 2024, then jumped by 1223.3% to $1.4 billion in 2025, then slumped by 85.18% to $202.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $202.0 million, $1.4 billion, and $51.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.